Skip to main content
915 TLDR
Health
1 read

Blue Cross Blue Shield Settlement: El Paso Residents to Benefit from $2.67 Billion Payout

KTSM••Jaylan Wright
Medical stethoscope representing healthcare news

Want the full story?

Read the complete article at KTSM

Read Original

AI Summary

A significant class-action settlement totaling $2.67 billion has been reached involving the Blue Cross Blue Shield Association, impacting millions of former policyholders across the United States, including those in El Paso. This agreement addresses antitrust claims against the association, ensuring that eligible customers will receive compensation. The payout is expected to provide financial relief to many who had health insurance through Blue Cross Blue Shield. Residents should stay informed about the claims process to ensure they receive their share of the settlement.

Key Details: • Settlement amount totals $2.67 billion for affected policyholders. • Eligible customers are those who previously held Blue Cross Blue Shield insurance. • Stay updated on the claims process for compensation details.

settlement health-insurance class-action antitrust blue-cross-blue-shield

People & Organizations

El PasoBlue Cross Blue Shield Association

Related Articles

KTSM•Apr 24

El Paso to Participate in National Prescription Drug Take Back Day This Saturday

This Saturday, April 25, the U.S. Drug Enforcement Administration (DEA) will conduct its 30th National Prescription Drug Take Back Day, providing a crucial opportunity for residents to safely dispose of unused or expired medications. The event will take place from 10 a.m. to 2 p.m. at nearly 4,200 locations across the country, including several in El Paso. This initiative is vital for preventing drug misuse and protecting the environment. Residents are encouraged to participate and help reduce the risk of prescription drug abuse in the community.

Health
1 min read
KTSM•Apr 24

Severe Health Risk: Flesh-Eating Bacteria Detected in New York Waters

A dangerous strain of flesh-eating bacteria has been identified in the waters of New York, raising significant health concerns. Individuals who contract this infection face a staggering 20% mortality rate within just 48 hours. This alarming statistic underscores the urgency for public awareness and precautionary measures, especially for those engaging in water activities. Residents are advised to stay informed about local water safety and health advisories to mitigate risks associated with this deadly bacteria.

Health
1 min read
KVIA•Apr 24

FDA Fast-Tracks Approval for Psychedelic Drugs in Mental Health Treatment

The FDA has expedited the review process for several psychedelic drugs aimed at treating mental health conditions, including psilocybin for treatment-resistant depression and PTSD. This initiative, part of a pilot program, could significantly reduce the time these treatments take to reach patients. A recent executive order from President Trump mandates the FDA to prioritize these therapies and includes a $50 million investment for state studies on their benefits. As the FDA continues to authorize clinical trials for psychedelics like ibogaine, the potential for these drugs to address the mental health crisis in the U.S. is gaining attention, particularly for veterans and those with severe mental health issues. However, the FDA warns that these substances, classified as Schedule I drugs, will only be available in controlled clinical settings if approved.

Health
1 min read
KVIA•Apr 24

FDA Fast-Tracks Psychedelic Drugs for Mental Health Treatments in the U.S.

The FDA has initiated a significant step towards the approval of psychedelic drugs as mental health treatments by issuing national priority vouchers to three companies. These include psilocybin for treatment-resistant depression and methylone for PTSD. This move, part of a pilot program aimed at expediting the review process, is crucial as it could provide new options for patients struggling with severe mental health issues. Additionally, an early phase clinical study of ibogaine for alcohol use disorder has been approved, marking a milestone in psychedelic research. Health officials emphasize the importance of rigorous clinical evidence as these treatments are explored.

Health
1 min read